A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

Phase 2 Completed 34 enrolled Eisai Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9 weeks of treatment.

Timeline

Start: 2021-02-25
Primary completion: 2021-12-08
Completion: 2022-01-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irsenontrine	Small molecule	50 mg	Oral

A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

Summary

Timeline

Drugs

Indications